May 11, 2020 / 7:14 PM / 23 days ago

EMA recommends expanding compassionate use of Gilead's COVID-19 drug

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake

(Reuters) - The European Medicines Agency (EMA) on Monday recommended that Gilead Sciences Inc’s experimental drug for the new coronavirus be given under compassionate use to patients other than those undergoing invasive mechanical ventilation.

The treatment can now be given to hospitalised patients requiring supplemental oxygen, non-invasive ventilation and high-flow oxygen devices, the agency said. (bit.ly/2YVjqMC)

Compassionate use is the use of an unauthorised medicine outside a clinical study in individual patients under strictly-controlled conditions.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below